The Mayo Clinic CRM Biotrust has the role of escalating promising cellular and acellular biologics from bench to clinical-grade products, through stringent quality and manufacturing practice documentation and validation. With the purchase of a clinical-grade cell sorter, the CRM Biotrust will further the integration and optimization of process development and CGMP manufacturing platforms and provide increased access to regenerative therapies.

Funding to equip laboratory space at the UMN Stem Cell Institute to provide a shared-space Innovation and Prototype Facility to support start-up companies and business/academic collaborations in the regenerative medicine business sector.

Equipment for CD34 cell isolation and selection in our planned cGMP operation for regenerative medicine.

This proposal aims to establish the state‐of‐the‐art ultrasound platform armed with photoacoustic technology specialized for regenerative therapies. This platform will be fully utilized in over 25 research projects at Mayo Clinic as well as educational activities for the next generation across the state of Minnesota.

The goal of this project is to prove that commercial production of regenerative proteins can be made consistently and with a significant cost reduction. There is a large commercial demand for products manufactured from these proteins if they can be made more cost effectively. MNPHARM's approach is a measurable improvement over current production methods of BMP2 where cost has prohibited the expansion of the medical treatments.